Journal of the Neurological Sciences
Volume 238, Issue 1 , Pages 31-39 , 15 November 2005

Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial

  • Masato Shibuya

      Affiliations

    • Chukyo Hospital, Nagoya, Japan
    • ,
  • Shunsaku Hirai

      Affiliations

    • Gunma University School of Medicine, Maebashi, Japan
    • ,
  • Minoru Seto

      Affiliations

    • Asahi Kasei Pharma Corporation, Shizuoka, Japan
    • ,
  • Shin-ichi Satoh

      Affiliations

    • Asahi Kasei Pharma Corporation, Shizuoka, Japan
    • Corresponding Author InformationCorresponding author. Scientific Affairs and Sales Promotion Dept., Asahi Kasei Pharma Corporation, 9-1, Kanda Mitoshirocho, Chiyoda-ku, Tokyo 101-8481, Japan. Tel.: +81 3 3259 5804; fax: +81 3 3259 5818.
    • ,
  • Eiichi Ohtomo

      Affiliations

    • Yokufukai Geriatric Hospital, Tokyo, Japan
    • ,
  • for the Fasudil Ischemic Stroke Study Group

Received 16 December 2004 ,Revised 6 June 2005 ,Accepted 6 June 2005.

References 

  1. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999;96:13496–13500
  2. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1992;76:571–577
  3. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105
  4. Ito K, Shimomura E, Iwanaga T, Shiraishi M, Shindo K, Nakamura J, et al. Essential role of rho kinase in the Ca2+ sensitization of prostaglandin F2α-induced contraction of rabbit aortae. J Physiol. 2003;546:823–836
  5. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol. 2000;20:2351–2358
  6. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm. Jpn Circ J. 2000;64:1–12
  7. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000;87:195–200
  8. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38:1307–1310
  9. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57–62
  10. Niggli V. Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett. 1999;445:69–72
  11. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension. Circ Res. 2001;88:774–779
  12. Kawaguchi A, Ohmori M, Harada K, Tsuruoka S, Sugimoto K, Fujimura A. The effect of a Rho kinase inhibitor Y-27632 on superoxide production, aggregation and adhesion in human polymorphonuclear leukocytes. Eur J Pharmacol. 2000;403:203–208
  13. Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol. 2001;154:147–160
  14. Shirao S, Kashiwagi S, Sato M, Miwa S, Nakao F, Kurokawa T, et al. Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery. Circ Res. 2002;91:112–119
  15. Satoh S, Ikegaki I, Suzuki Y, Asano T, Shibuya M, Hidaka H. Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br J Pharmacol. 1996;118:1592–1596
  16. Satoh S, Utsunomiya T, Tsurui K, Kobayashi T, Ikegaki I, Sasaki Y, et al. Pharmacological profile of hydroxyl fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001;69:1441–1453
  17. Toshima Y, Satoh S, Ikegaki I, Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke. 2000;31:2245–2250
  18. Satoh S, Kobayashi T, Hitomi A, Ikegaki I, Suzuki Y, Shibuya M, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol. 1999;80:41–48
  19. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol. 2002;455:169–174
  20. Arai M, Sasaki Y, Nozawa R. Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem Pharmacol. 1993;46:1487–1490
  21. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses Angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ Res. 2003;93:767–775
  22. Tsuchiya M, Sako K, Yonemasu Y, Asano T. The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats. Exp Brain Res. 1993;97:233–238
  23. Nagata K, Kondoh Y, Satoh Y, Watahiki Y, Yokoyama E, Yuya H, et al. Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. Clin Neuropharmacol. 1993;16:501–510
  24. Hitomi A, Satoh S, Ikegaki I, Suzuki Y, Shibuya M, Asano T. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci. 2000;67:1929–1939
  25. Gotoh F, Terayama Y, Amano T. Development of a novel, weighted, quantifiable stroke scale. Stroke. 2001;32:1800–1807
  26. Watari N, Benet LZ. Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs. J Pharmacokinet Biopharm. 1989;17:593–599
  27. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke. 1996;27:1739–1743
  28. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997;20:132–139
  29. Szikszai Z, Fekete I, Imre SG. A comparative study of hemorheological parameters in transient ischemic attack and acute ischemic stroke patients: possible predictive value. Clin Hemorheol Microcirc. 2003;28:51–57
  30. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol. 2003;62:127–136
  31. Lees KR, Diener H-C, Asplund K, Krams M. UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke. Stroke. 2003;34:1704–1709

PII: S0022-510X(05)00221-2

doi: 10.1016/j.jns.2005.06.003

Journal of the Neurological Sciences
Volume 238, Issue 1 , Pages 31-39 , 15 November 2005

Article Tools

* Image Usage & Resolution